At the end of 2023, the agency approved repotrectinib for ROS1+ NSCLC, granted priority review for tarlatamab for advanced SCLC, and asked for an additional confirmatory trial for sotorasib for KRAS G12C-mutated NSCLC. Read more
IASLC names J. Michael Hoehn COO. FDA approves adagrasib for KRAS G12C-mutated NSCLC. NHS England increases access to screening in effort to catch cancers earlier. Read more
Learn how new guidance from the UK’s National Institutes for Health Care Excellence addresses an unmet clinical need for patients with EGFR+ NSCLC with exon 20 insertion and stay up to date on the latest meeting news from IASLC. Read more
By Erik MacLaren, PhD Posted: August 21, 2020 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Merck’s immune checkpoint inhibitor pembrolizumab, adding a new tissue-agnostic indication […] Read more
Posted: February 12, 2020 December 12, 2019—Stephen M. Hahn, MD, FASTRO, was confirmed as commissioner of the U.S. Food and Drug Administration by a Senate vote of 72 to 18. […] Read more
Posted: December 11, 2019 In June 2019, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence launched Project Facilitate, a call center that assists oncology healthcare professionals with […] Read more
By Erik MacLaren, PhD Posted: April 1, 2019 On January 25, 2019, the Director of the National Cancer Institute (NCI) Norman E. Sharpless, MD, participated in a live social media event […] Read more
Posted: December 2018 Richard Pazdur, MD, is director of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence. Below, he discusses the current status of and future directions […] Read more
Posted: December 2018 Investigators at the National Cancer Institute (NCI) compared the transcriptional profiles of lung cancers from African American patients to those from white patients and identified molecular differences […] Read more
NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy
Posted: August 2018 In October 2017, the United States National Cancer Institute (NCI) launched a major effort to expand the discovery and validation of predictive biomarkers on cancer immunotherapy. This […] Read more